Dr. Alexander Menter

About Alexander Menter

Education:

• Obtained a Medical Degree (MD) from the University of Colorado School of Medicine in 2015.
• Completed a Residency in Internal Medicine at the University of Colorado Hospital in 2018.
• Finished a Fellowship in Hematology/Oncology at the University of Colorado Anschutz Medical Campus in 2021.

Experience:

• Currently practices as a Hematologist/Oncologist at Kaiser Permanente Lone Tree Medical Offices.

Area of expertise

Affiliated Hospitals

Kaiser Permanente-Franklin

Kaiser Permanente-Rock Creek

Clinical Trials Alexander Menter is currently running

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting2 awards Phase 331 criteria

High-Dose vs Low-Dose Cisplatin with Radiation

for Head and Neck Cancer

This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer.

Recruiting1 award Phase 2 & 335 criteria

More about Alexander Menter

Other Doctors you might be interested in

Frequently asked questions